MEDICAL NEWS
Untitled Page
Spectrum stops drug therapy production, continued ...
"This is part of a concerted effort at streamlining and prioritizing our portfolio," adds Shrotriya.
The company also announced this week that it is moving forward with its November apaziquone collaboration deal. The firm received $15 million from Nippon Kayaku and $1 million from Handok Pharmaceuticals. The former will develop and commercialize the bladder cancer drug in Asian territories, while the latter will operate in South Korea.
The total value of its Asian-market partnerships is more than $170 million, according to Spectrum.
<< PREVIOUS PAGE
Related headlines
Irvine-based Neomend raises $30 million
Irvine's Tech Coast Angels ramps up entrepreneurial support
State of the Union address focuses on jobs, economy
Spectrum stops drug therapy production, continued ...
"This is part of a concerted effort at streamlining and prioritizing our portfolio," adds Shrotriya.The company also announced this week that it is moving forward with its November apaziquone collaboration deal. The firm received $15 million from Nippon Kayaku and $1 million from Handok Pharmaceuticals. The former will develop and commercialize the bladder cancer drug in Asian territories, while the latter will operate in South Korea.
The total value of its Asian-market partnerships is more than $170 million, according to Spectrum.
<< PREVIOUS PAGE
Related headlines
Irvine-based Neomend raises $30 million
Irvine's Tech Coast Angels ramps up entrepreneurial support
State of the Union address focuses on jobs, economy
